Collegium Pharmaceutical Stock (NASDAQ:COLL)
Previous Close
$36.53
52W Range
$20.95 - $40.95
50D Avg
$35.21
200D Avg
$34.10
Market Cap
$1.21B
Avg Vol (3M)
$441.77K
Beta
0.93
Div Yield
-
COLL Company Profile
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
COLL Performance
Revenue Breakdown
Revenue Breakdown by Product/Service
| Product/Service | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|
| Nucynta IR | $108.15M | $112.06M | $102.22M |
| Symproic | $16.50M | $12.27M | - |
| Xtampza ER | $177.37M | $138.80M | $103.71M |
| Belbuca | $182.09M | $126.46M | - |
| Nucynta ER | $82.65M | $72.42M | $70.94M |
| Other | - | $1.93M | - |
| Nucynta Products | - | - | $173.16M |
Fiscal year ends in Dec 23 | Currency in USD
Peer Comparison
| Ticker | Company |
|---|---|
| ITCI | Intra-Cellular Therapies, Inc. |
| RDY | Dr. Reddy's Laboratories Limited |
| ANIP | ANI Pharmaceuticals, Inc. |
| PAHC | Phibro Animal Health Corporation |
| RGC | Regencell Bioscience Holdings Limited |
| SSIC | Silver Spike Investment Corp. |
| PROC | Procaps Group S.A. |
| PBH | Prestige Consumer Healthcare Inc. |
| ALKS | Alkermes plc |
| PCRX | Pacira BioSciences, Inc. |
| EGRX | Eagle Pharmaceuticals, Inc. |
| EOLS | Evolus, Inc. |
| AMPH | Amphastar Pharmaceuticals, Inc. |